Thyrocare Technologies Ltd vs Vaidya Sane Ayurved Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 31, 2026

Key Highlights

The Latest Trading Price of Thyrocare Technologies Ltd is ₹ 457 as of 30 Oct 15:30 . The P/E Ratio of Thyrocare Technologies Ltd changed from 42.2 on March 2021 to 34.2 on March 2026 . This represents a CAGR of -3.44% over 6 yearsThe P/E Ratio of Vaidya Sane Ayurved Laboratories Ltd changed from 51.1 on March 2023 to 19.5 on March 2026 . This represents a CAGR of -21.40% over 4 years The Market Cap of Thyrocare Technologies Ltd changed from ₹ 4774 crore on March 2021 to ₹ 5566 crore on March 2026 . This represents a CAGR of 2.59% over 6 yearsThe Market Cap of Vaidya Sane Ayurved Laboratories Ltd changed from ₹ 247.07 crore on March 2023 to ₹ 175.15 crore on March 2026 . This represents a CAGR of -8.24% over 4 years The revenue of Thyrocare Technologies Ltd for the Sep '26 is ₹ 275.24 crore as compare to the Jun '26 revenue of ₹ 244.88 crore. This represent the growth of 12.4% The revenue of Vaidya Sane Ayurved Laboratories Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Thyrocare Technologies Ltd for the Sep '26 is ₹ 48.74 crore as compare to the Jun '26 ebitda of ₹ 82.13 crore. This represent the decline of -40.66% The ebitda of Vaidya Sane Ayurved Laboratories Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Thyrocare Technologies Ltd changed from ₹ 23.94 crore to ₹ 15.22 crore over 10 quarters. This represents a CAGR of -16.57% The net profit of Vaidya Sane Ayurved Laboratories Ltd changed from ₹ 0 crore to ₹ 0 crore over 10 quarters. This represents a CAGR of 0.0% The Dividend Payout of Thyrocare Technologies Ltd changed from 110.36 % on March 2021 to 149.75 % on March 2026 . This represents a CAGR of 5.22% over 6 yearsThe Dividend Payout of Vaidya Sane Ayurved Laboratories Ltd changed from 5.06 % on March 2023 to 0 % on March 2026 . This represents a CAGR of -100.00% over 4 years .

About Thyrocare Technologies Ltd

Thyrocare Technologies Limited was incorporated in January, 2000.
The Company operates in the healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India. As of 31 March 2025, the Company offered more than 920 distinct tests that support early detection, preventive care and the ongoing disease monitoring.
Their 43 profiles are administered under its reputed 'Aarogyam' brand, which offers patients a suite of wellness and preventive health care tests.
The Company primarily operates its testing services through a fully automated Centralised Processing Laboratory (the CPL) and has expanded its operations to include a network of Regional Processing Laboratories (RPLs).
The company currently operates 25 RPLs, one in each of New Delhi, Coimbatore, Hyderabad, Kolkata, Bangalore, Bhopal, Mumbai Patna and Chennai, which process samples sourced from their respective regions.

About Vaidya Sane Ayurved Laboratories Ltd

Vaidya Sane Ayurved Laboratories Limited was originally incorporated as a Private Limited Company pursuant to a Certificate of Incorporation issued by the Registrar of Companies, Pune dated April 6, 1999 with the name Vaidya Sane Ayurved Laboratories Private Limited'.
Subsequently, Company was converted into to a Public Limited Company and the name of Company was changed to Vaidya Sane Ayurved Laboratories Limited'.
A fresh Certificate of Incorporation upon conversion was issued on November 25, 2021 by the Registrar of Companies, Pune. The Company is a unique medical service institution to treat chronic ailments like cardiac disease, diabetes, hypertension and obesity with the distinctive outlook of amalgamating technology with traditional healing of Ayurveda.
Its approach to treatment using non-invasive, multidisciplinary and innovative therapies has helped the Company for treating the chronic ailments.

FAQs for the comparison of Thyrocare Technologies Ltd and Vaidya Sane Ayurved Laboratories Ltd

Which company has a larger market capitalization, Thyrocare Technologies Ltd or Vaidya Sane Ayurved Laboratories Ltd?

Market cap of Thyrocare Technologies Ltd is 7,273 Cr while Market cap of Vaidya Sane Ayurved Laboratories Ltd is 142 Cr

What are the key factors driving the stock performance of Thyrocare Technologies Ltd and Vaidya Sane Ayurved Laboratories Ltd?

The stock performance of Thyrocare Technologies Ltd and Vaidya Sane Ayurved Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Thyrocare Technologies Ltd and Vaidya Sane Ayurved Laboratories Ltd?

As of October 31, 2026, the Thyrocare Technologies Ltd stock price is INR ₹457.0. On the other hand, Vaidya Sane Ayurved Laboratories Ltd stock price is INR ₹136.0.

How do dividend payouts of Thyrocare Technologies Ltd and Vaidya Sane Ayurved Laboratories Ltd compare?

To compare the dividend payouts of Thyrocare Technologies Ltd and Vaidya Sane Ayurved Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.